CalciMedica

CalciMedica

Leader in the development of CRAC channel inhibitor drugs for inflammatory diseases

Founded 2007

La Jolla, United States 13 employees Post-IPO Equity Total: $160.80M Health Care, Information Technology +1

CalciMedica is a leader in the development of CRAC channel inhibitor drugs for inflammatory diseases. Founded in 2006 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA, the company is a privately held, clinical-stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. Dr. Stauderman’s work includes the discovery of the role of STIM1, which works in concert with Orai1 in the CRAC channels targeted by CalciMedica’s drugs. The company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications. It has also assembled a portfolio of patents and patent applications covering those compounds as well as different aspects of CRAC channel biology. In January 22, 2024, CalciMedica secured a $55.00M post-IPO equity investment from a consortium of investors including Aisling Capital, Bering Capital, Deerfield Management, Sanderling Ventures, Soleus Capital, and Stonepine Capital Management. The company is headquartered in the United States and operates in the Health Care and Information Technology industries. With its focus on developing innovative drugs for acute and severe inflammatory diseases, CalciMedica presents an attractive opportunity for venture capital investment in the biotechnology sector.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$55.00M	6	Aisling Capital, Bering Capital +4	22 Jan 2024
Venture Round	$10.34M	-		04 Apr 2023
Series D	$21.00M	4	GHS Fund, Sanderling Ventures +2	11 Mar 2021
Series C	$15.00M	4	Bering Capital, Mesa Verde Venture Partners +2	22 May 2020
Venture Round	$2.50M	-		24 Apr 2014
Debt Financing	$3.00M	-		16 Jul 2013
Debt Financing	$4.60M	-		05 Nov 2012
Debt Financing	$13.20M	-		02 Apr 2012
Debt Financing	$4.00M	-		29 Sep 2011
Debt Financing	$9.16M	-		08 Feb 2011

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$55.00M

Aisling Capital, Bering Capital +4

22 Jan 2024

Venture Round

$10.34M

04 Apr 2023

Series D

$21.00M

GHS Fund, Sanderling Ventures +2

11 Mar 2021

Series C

$15.00M

Bering Capital, Mesa Verde Venture Partners +2

22 May 2020

Venture Round

$2.50M

24 Apr 2014

Debt Financing

$3.00M

16 Jul 2013

Debt Financing

$4.60M

05 Nov 2012

Debt Financing

$13.20M

02 Apr 2012

Debt Financing

$4.00M

29 Sep 2011

Debt Financing

$9.16M

08 Feb 2011

FAQ About CalciMedica

Leader in the development of CRAC channel inhibitor drugs for inflammatory diseases

CalciMedica was founded in 2007.

CalciMedica is headquartered in La Jolla, United States.

CalciMedica operates in Health Care, Information Technology and Life Sciences. Its work centres on drug discovery, inflammatory diseases, CRAC channel and clinical stage.

CalciMedica has approximately 13 employees.

CalciMedica has completed 14 funding rounds, raising a total of $160.80M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to CalciMedica include Kezar Life Sciences, Third Harmonic Bio, Pharvaris, Pacylex Pharmaceuticals, Inc., Tridek-One. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

CalciMedica and Kezar Life Sciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About CalciMedica

Funding Rounds & Investors (14)

CalciMedica Alternatives & Competitors

FAQ About CalciMedica